Edit Entry | Edit CV

Steven Woloshin, MD

Title(s)
Professor of The Dartmouth Institute
Professor of Medicine
Professor of Community and Family Medicine

Department(s)
The Dartmouth Institute
Medicine
Community and Family Medicine

Education
Dartmouth Medical School, MS 1996
Boston University School of Medicine, MD 1987
Boston University, BA 1987

Programs
The Dartmouth Institute for Health Policy and Clinical Practice

Contact Information

Dartmouth Medical School
HB 7900
Hanover NH 03755

Phone: 603 646 5672
Email: steven.woloshin@dartmouth.edu


Professional Interests

Dr. Woloshin's research interest is in learning how to enhance the quality of medical communication to the public, patients, physicians and policymakers. His work (in collaboration with Dr. Lisa Schwartz) has 2 main approaches: improving the quality of messages presenting health information to people, and preparing audiences to make sense of the messages they receive. His main focus is on the communication of medical statistics and information about the benefits and harms of screening and prescription drugs.


Selected Publications

 

What evidence is required to justify the NHS Health Check programme?
Jorgensen KJ, Johansson M, Woloshin S
BMC Med. 2025 Apr 24;23(1):242. doi: 10.1186/s12916-025-04081-3. Epub 2025 Apr 24.
PMID: 40275326

Alternative Presentations of Overall and Statistical Uncertainty for Adults' Understanding of the Results of a Randomized Trial of a Public Health Intervention: Parallel Web-Based Randomized Trials.
Holst C, Woloshin S, Oxman AD, Rose C, Rosenbaum S, Munthe-Kaas HM
JMIR Public Health Surveill. 2025 Mar 18;11:e62828. doi: 10.2196/62828. Epub 2025 Mar 18.
PMID: 40101228

Corrigendum to "Tobacco Product Use and Functionally Important Respiratory Symptoms Among US Adolescents/Young Adults" [Acad Pediatr. 2022; 22(6):1006-1016].
Tanski S, Halenar MJ, Edwards KC, Emond J, Woloshin S, Brunette M, Schwartz L, Taylor KA, Goniewicz ML, Niaura R, Anic G, Chen Y, Callahan-Lyon P, Gardner LD, Thekkudan T, Borek N, Kimmel HL, Michael Cummings K, Hyland A, Sargent J
Acad Pediatr. 2025 Apr;25(3):102561. doi: 10.1016/j.acap.2024.08.006. Epub 2025 Feb 7.
PMID: 39922078

Physician-Patient Communication about Novel Drugs and High-Risk Medical Devices.
Dhruva SS, Kesselheim AS, Woloshin S, Ji RZ, Lu Z, Darrow JJ, Redberg RF
Med Decis Making. 2025 Feb;45(2):156-167. doi: 10.1177/0272989X241302096. Epub 2024 Dec 21.
PMID: 39707817

Direct-to-consumer tests: emerging trends are cause for concern.
Gram EG, Copp T, Ransohoff DF, Pluddemann A, Kramer BS, Woloshin S, Shih P
BMJ. 2024 Dec 4;387:e080460. doi: 10.1136/bmj-2024-080460. Epub 2024 Dec 4.
PMID: 39631937

Patients deserve better information on new drugs.
Davis C, Wagner AK, Mintzes B, Scowcroft H, Woloshin S, Naci H
BMJ. 2024 Oct 29;387:e081720. doi: 10.1136/bmj-2024-081720. Epub 2024 Oct 29.
PMID: 39471990

Website Content and Funding of Officially Recognized Disease Awareness Campaigns.
Johansson M, Albarqouni L, O'Keeffe M, Jorgensen KJ, Woloshin S
JAMA. 2024 Aug 20;332(7):589-592. doi: 10.1001/jama.2024.12267.
PMID: 39052249

Call to improve transparent communication in direct-to-consumer test marketing.
Gram EG, Macdonald H, Kramer B, Woloshin S, Preventing Overdiagnosis Scientific Committee
BMJ Evid Based Med. 2024 Jul 23;29(4):213-214. doi: 10.1136/bmjebm-2024-112959. Epub 2024 Jul 23.
PMID: 38937068

Patient perspectives on evidence supporting drug safety and effectiveness: "What does it mean for me?".
Rand LZG, McGraw S, Wang J, Woloshin S, Wang SV, Darrow J, Kesselheim AS
J Am Geriatr Soc. 2024 Sep;72(9):2874-2877. doi: 10.1111/jgs.19015. Epub 2024 May 30.
PMID: 38813805

Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis.
Naci H, Zhang Y, Woloshin S, Guan X, Xu Z, Wagner AK
Lancet Oncol. 2024 Jun;25(6):760-769. doi: 10.1016/S1470-2045(24)00152-9. Epub 2024 May 13.
PMID: 38754451

View more publications on PubMed